期刊
PHARMACEUTICS
卷 14, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14051014
关键词
intranasal immunization; Zika virus; domain III; mucosal vaccine
资金
- Ministry of Science and Technology, Taiwan [MOST110-2327-B-007-004, MOST109-2313-B-007-001-MY2, MOST108-2321-B-002-006]
- MacKay Memorial Hospital, Taiwan [MMH-TH-11005, MMH-TH-11008]
In this study, a recombinant ZIKV envelope DIII protein genetically fused with Salmonella typhimurium flagellin was developed as a mucosal antigen. Intranasal immunization with this antigen elicited strong protective immunity against ZIKV challenges, demonstrating its potential for developing mucosal vaccines.
Zika virus (ZIKV) infections in humans are mainly transmitted by the mosquito vectors, but human-to-human sexual transmission is also another important route. Developing a ZIKV mucosal vaccine that can elicit both systemic and mucosal immune responses is of particular interest. In this study, we constructed a recombinant ZIKV envelope DIII (ZDIII) protein genetically fused with Salmonella typhimurium flagellin (FliC-ZDIII) as a novel mucosal antigen for intranasal immunization. The results indicated that the FliC-ZDIII fusion proteins formulated with E. coli heat-labile enterotoxin B subunit (LTIIb-B5) adjuvant greatly increased the ZDIII-specific IgG, IgA, and neutralizing titers in sera, and the ZDIII-specific IgA titers in bronchoalveolar lavage and vaginal fluids. Protective immunity was further assessed by subcutaneous and intravaginal ZIKV challenges. The second-generation FliC Delta D3-2ZDIII was shown to result in a reduced titer of anti-FliC IgG antibodies in sera and still retained the same levels of serum IgG, IgA, and neutralizing antibodies and mucosal IgA antibodies without compromising the vaccine antigenicity. Therefore, intranasal immunization with FliC Delta D3-2ZDIII fusion proteins formulated with LTIIb-B5 adjuvant elicited the greatest protective immunity against subcutaneous and intravaginal ZIKV challenges. Our findings indicated that the combination of FliC Delta D3-2ZDIII fusion proteins and LTIIb-B5 adjuvant for intranasal immunization can be used for developing ZIKV mucosal vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据